Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
Memorial Sloan Kettering Cancer Center · Cornell University · +43 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
532
total citations
- FWCI
- 43.82
- Percentile
- 100%
- References
- 30
Citations per year
Authors
36- ADAlexander Drilon
Memorial Sloan Kettering Cancer Center, Cornell University
- SSSalvatore Siena
University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- RDRafał Dziadziuszko
Gdańsk Medical University
- FBFabrice Barlési
Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille
- MKMatthew Krebs
Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust
Topics & keywords
Topics
Keywords
- Medicine
- ROS1
- Internal medicine
- Oncology
- Lung cancer
- Population
- Cancer
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.